Open Access

Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study

  • Authors:
    • Yoshiji Yamada
    • Kota Matsui
    • Ichiro Takeuchi
    • Mitsutoshi Oguri
    • Tetsuo Fujimaki
  • View Affiliations

  • Published online on: March 20, 2015     https://doi.org/10.3892/ijmm.2015.2151
  • Pages: 1189-1198
  • Copyright: © Yamada et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We previously identified 9 genes and chromosomal region 3q28 as susceptibility loci for Japanese patients with myocardial infarction, ischemic stroke, or chronic kidney disease by genome-wide or candidate gene association studies. In the present study, we investigated the possible association of 13 single nucleotide polymorphisms (SNPs) at these 10 loci with the prevalence of hypertension or their association with blood pressure (BP) in community-dwelling individuals in Japan. The study subjects comprised 6,027 individuals (2,250 subjects with essential hypertension, 3,777 controls) who were recruited into the Inabe Health and Longevity Study, a longitudinal genetic epidemiological study on atherosclerotic, cardiovascular and metabolic diseases. The subjects were recruited from individuals who visited the Health Care Center of Inabe General Hospital for an annual health checkup, and they are followed up each year (mean follow‑up period, 5 years). Longitudinal analysis with a generalized estimating equation and with adjustment for age, gender, body mass index and smoking status revealed that rs2116519 of family with sequence similarity 78, member B (FAM78B; P=0.0266), rs6929846 of butyrophilin, subfamily 2, member A1 (BTN2A1; P=0.0013), rs146021107 of pancreatic and duodenal homeobox 1 (PDX1; P=0.0031) and rs1671021 of lethal giant larvae homolog 2 (Drosophila) (LLGL2; P=0.0372) were significantly (P<0.05) associated with the prevalence of hypertension. Longitudinal analysis with a generalized linear mixed-effect model and with adjustment for age, gender, body mass index and smoking status among individuals not taking anti-hypertensive medication revealed that rs6929846 of BTN2A1 was significantly associated with systolic (P=0.0017), diastolic (P=0.0008) and mean (P=0.0005) BP, and that rs2116519 of FAM78B, rs146021107 of PDX1 and rs1671021 of LLGL2 were significantly associated with diastolic (P=0.0495), systolic (P=0.0132), and both diastolic (P=0.0468) and mean (0.0471) BP, respectively. BTN2A1 may thus be a susceptibility gene for hypertension.

Introduction

Hypertension is a complex multifactorial disorder that is thought to result from an interaction between an individual’s genetic background and various lifestyle and environmental factors (1). The genetic influence on blood pressure (BP) variability has been estimated at 30–60% for a given individual (2), and the genetic heritability of hypertension estimated at 30% (3). Given that hypertension is a major risk factor for coronary artery disease, ischemic and hemorrhagic stroke, as well as chronic kidney disease (46), the personalized prevention of hypertension is an important public health goal.

Genome-wide association studies have identified various loci and genes associated with BP or to a predisposition to hypertension in Caucasian populations (711) or African Americans (12). Although the genes for adducin 2 (13) and ATPase, Ca2+ transporting, plasma membrane 1 (14) have been shown to be susceptibility loci for hypertension in Japanese individuals, the genes that confer susceptibility to this condition in Japanese individuals remain to be identified definitively.

We have previously identified 9 genes and chromosomal region 3q28 as susceptibility loci for myocardial infarction, ischemic stroke, or chronic kidney disease in Japanese individuals by genome-wide (1517) or candidate gene (1820) association studies. Given that hypertension is an important risk factor for these conditions (46), we hypothesized that certain single nucleotide polymorphisms (SNPs) at these 10 loci may contribute to their genetic susceptibility by affecting the susceptibility to hypertension. Therefore, the purpose of the present study was to examine the possible association of 13 SNPs at these 10 loci with the prevalence of essential hypertension or their association with BP in community-dwelling Japanese individuals.

Materials and methods

Study population

Study subjects comprised 6,027 community-dwelling individuals (2,250 subjects with essential hypertension and 3,777 controls) who were recruited to a population-based cohort study in Inabe City (Inabe Health and Longevity Study), Mie Prefecture, Japan. The Inabe Health and Longevity Study is a longitudinal genetic epidemiological study of atherosclerotic, cardiovascular and metabolic diseases (2126). The subjects were recruited from individuals who visited the Health Care Center of Inabe General Hospital for an annual health checkup, and they are followed up each year. A total of 6,027 individuals was registered between March 2010 and September 2012, and genomic DNA was extracted from the venous blood cells of these subjects and stored in the genomic DNA bank of the Research Center for Genomic Medicine at Mie University. For all the participants, medical examination data obtained from April 2003 to March 2014 (11 years) were entered into a database. If individuals had a medical checkup 2 or more times per year, data from one time point for each year were entered, so that each subject had one set of health data for each year they had attended the clinic. All participants thus had undergone 1–11 medical examinations, and the average follow-up period was 5 years.

Subjects with hypertension either had a systolic BP of ≥140 mmHg or a diastolic BP of ≥90 mmHg (or both) or had taken anti-hypertensive medication. The control individuals had a systolic BP of <140 mmHg and a diastolic BP of <90 mmHg, as well as no history of hypertension or of taking any anti-hypertensive medication. BP was measured at least twice with the subjects having rested in the sitting position for >5 min; the measurements were taken by a skilled physician or nurse according to the guidelines of the American Heart Association (27). The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine and Inabe General Hospital. Written informed consent was obtained from all subjects prior to enrollment in the study.

Selection and genotyping of polymorphisms

The 13 SNPs examined in the present study (Table I) were selected from our previous genome-wide (1517) or candidate gene (1820) association studies. Wild-type (ancestral) and variant alleles of the SNPs were determined from the dbSNP database (National Center for Biotechnology Information, Bethesda, MD, USA) (http://www.ncbi.nlm.nih.gov/SNP).

Table I

The 13 SNPs examined in the present study.

Table I

The 13 SNPs examined in the present study.

Chromosomal locusGenedbSNP (NCBI)Nucleotide substitutionMinor allelea
1q24.1FAM78Brs2116519C→TC
3q28Non-gene regionrs9846911A→GG
4q25ALPK1rs2074379G→A (Met732Ile)G
4q25ALPK1rs2074380G→A (Gly870Ser)A
4q25ALPK1rs2074381A→G (Asn916Asp)G
4q25ALPK1rs2074388G→A (Gly565Asp)G
6p22.1BTN2A1rs6929846T→CT
6q27THBS2rs8089T→GG
13q12.1PDX1rs146021107G→- (deletion)
13q34F7rs6046G→A (Arg353Gln)A
17q25.1LLGL2rs1671021G→A (Leu479Phe)G
19p13.2ILF3rs2569512G→AA
22q13.3CELSR1rs6007897C→T (Ala2268Thr)C

a The minor allele in Japanese individuals was determined by the allele frequency of HapMap-JPT in dbSNP. SNPs, single nucleotide polymorphisms.

Venous blood (5 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), and peripheral blood leukocytes were isolated and genomic DNA was extracted from these cells with the use of a DNA extraction kit (SMITEST EX-R&D; Medical and Biological Laboratories, Nagoya, Japan). The genotypes of the 13 SNPs were determined at G&G Science Co., Ltd. (Fukushima, Japan) by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX, USA). The primers, probes and other conditions for the genotyping of the SNPs examined in the present study are shown in Table II. Detailed genotyping methodology was as described previously (15,16,28).

Table II

Primers, probes and other conditions for the genotyping of the 13 SNPs examined in the present study.

Table II

Primers, probes and other conditions for the genotyping of the 13 SNPs examined in the present study.

Gene or locusSNPdbSNPSense primer (5′→3′)Antisense primer (5′→3′)Probe 1 (5′→3′)Probe 2 (5′→3′)Annealing(°C) Cycles
FAM78BC→Trs2116519 CCTGCACTGCTCTAGCTACTTC GATCCCAATTTCAACTGTGAGATC TCATTCCGGTCTCAGCCGCT CCCTCATTCCGGTTTCAGCC6050
3q28A→Grs9846911 AGTTGTGTGCCAGATTCTCCAG TCTTCACTGAGACCTTGGGAAG TCTCCTCTTTCAATAACAAATCTTC AAAGTCTCCTCTTTCAGTAACAAAT6050
ALPK1G→Ars2074379 TCTGCTTCTTGGTCTTCTGATTC AGTTGGTTTCTGGAAACTCAACAA GAAGGATGTGTGCCTATATTCTT GATGTGTGCCCATATTCTTGGG6050
ALPK1G→Ars2074380 CTCCACAGTGGATGAGGAGG CTTACAGAGGAATTGGGGGTC ACAAATGGGCACAGCTCTCATA TATGAGAGCCGTGCCCATTTGT6050
ALPK1A→Grs2074381 AGGACTGCACTACCACAGAGG TGATTTCAGCCACCACACTGAG ATCAGCCTGGAAACATGCTAAAC AGTTTAGCATGTCTCCAGGCTG6050
ALPK1G→Ars2074388 TGTGGAGACTGAGACTGAGCC TTGCTCCAAGCACTGGAAGTC ACTACAGCAATGATGAGGGAGC GCTCCCTCACCATTGCTGTAG6050
BTN2A1T→Crs6929846 CCAAACATGGCGACCTAGGAGA ATCTGCCCAGGGGCACAGGC TTTGGGAAGGTTTGCGTCTAG TTTGGGAAGGTTTGTGTCTAGT6050
THBS2T→Grs8089 AACCCAAGTGCCTTCAGAGGAT CTCCACATAAAGTCTCATATATCAC GATGTTCATCTCTGAGTTCCA GATGTTCATCTCTGCGTTCCA6050
PDX1G→-rs146021107 TGGCTGTGGGTTCCCTCTGAG GATTTGGCACTGTGTGGCGTTC CGAGCAGGGGTGGCGCC GGCGCCACCCTGCTCGCT6050
F7G→Ars6046 CGGCTACTCGGATGGCAGCA CCAAAGTGGCCCACGGTTGC TACCACGTGCCCCGGTAGTG GCCACCCACTACCAGGGCA6050
LLGL2G→Ars1671021 GCTCCTGGCCTCACCTTGCG GCTGCTCTACAAACTCAGCACTG CTGGGCACTGAAGTTCTCGTT CCAACGAGAACCTCAGTGCC6050
ILF3G→Ars2569512 ACCACCTCAACTGCAAGCTGAA GGAATGATCCCTCTGGGAAGGT GTGCAACTGCCAAAAACTGGT GTGCAACTGCCAAGAACTGG6050
CELSR1C→Trs6007897 GGAGACGGAGGACTCCAGCTC CTTGCTGTCGACATCTTTGACAAG TCTTCATGGATGGCGTCGAAT TCTTCATGGATGGTGTCGAATC6050

[i] SNPs, single nucleotide polymorphisms.

Statistical analysis

Quantitative data were compared between the subjects with hypertension and the controls with the unpaired Student’s t-test. Categorical data were compared with the χ2 test. We examined the association of the 13 SNPs with the prevalence of hypertension or their association with systolic, diastolic, or mean BP based on a 5-year longitudinal cohort study. Longitudinal changes in the prevalence of hypertension were compared between 2 groups (the dominant or recessive genetic model) with a generalized estimating equation, as previously described (29) and with adjustment for age, gender, body mass index (BMI) and smoking status. Longitudinal changes in systolic, diastolic, or mean BP in all the individuals or in the individuals not any taking anti-hypertensive medication were compared between 2 groups (the dominant or recessive model) in a generalized linear mixed-effect model, as previously described (30) with adjustment for age, gender, BMI and smoking status. The dominant or recessive model was defined as AA vs. AB + BB or AA + AB vs. BB (A, major allele; B, minor allele), respectively. Age-related changes in the prevalence of hypertension or in systolic or diastolic BP were estimated with quadratic curves controlling for the observation year. A P-value <0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using R software version 3-0-2 (the R Project for Statistical Computing) and JMP Genomics version 6.0 (SAS Institute, Cary, NC, USA).

Results

Characteristics of the 6,027 study subjects (3,352 males, 2,675 females) with regard to all measurements in a 5-year follow-up are shown in Table III. Characteristics of the subjects with hypertension and the controls according to cross-sectional analysis in March 2014 are shown in Table IV. Age, the frequency of the male gender, BMI and the prevalence of smoking were greater in the subjects with hypertension than in the controls.

Table III

Characteristics of the study subjects: analysis of all measurements in a 5-year follow-up.

Table III

Characteristics of the study subjects: analysis of all measurements in a 5-year follow-up.

ParameterMaleaFemaleaAlla
No. of subjects335226756027
Age (years)52.5±12.5 (15,959)52.5±11.9 (12,572)52.5±12.2 (28,531)
Height (cm)168.4±6.6 (15,550)155.2±5.9 (12,373)162.6±9.1 (27,923)
Weight (kg)67.0±11.0 (15,548)53.5±8.2 (12,373)61.0±12.0 (27,921)
Body mass index (kg/m2)23.6±3.3 (15,548)22.2±3.2 (12,373)23.0±3.3 (27,921)
Waist circumference (cm)83.2±8.7 (11,817)77.8±9.0 (9,541)80.8±9.2 (21,358)
Alcohol concumption (%)67.4 (15,959)26.4 (12,572)49.3 (28,531)
Current or former smoker (%)65.0 (15,959)8.5 (12,572)40.1 (28,531)
Systolic blood pressure (mmHg)122±16 (15,541)119±16 (12,370)121±16 (27,911)
Diastolic blood pressure (mmHg)77±12 (15,541)71±11 (12,370)75±12 (27,911)
Mean blood pressure (mmHg)92±13 (15,541)87±12 (12,370)90±13 (27,911)
Ocular tension (right, mmHg)14.0±3.0 (6,132)13.4±2.8 (4,886)13.7±3.0 (11,018)
Functional vital capacity (l)3.53±0.66 (6,173)2.55±0.47 (4,865)3.10±0.76 (11,038)
FEV1% (%)82.3±7.1 (6,168)84.8±6.7 (4,865)83.4±7.0 (11,033)
Serum albumin (g/l)44.5±2.9 (10,332)44.1±2.7 (8,510)44.3±2.8 (18,842)
Serum total cholesterol (mmol/l)5.15±0.88 (15,121)5.31±0.88 (11,887)5.22±0.89 (27,008)
Serum triglyceride (mmol/l)1.46±1.06 (15,639)1.01±0.58 (12,401)1.26±0.91 (28,040)
Serum HDL-cholesterol (mmol/l)1.47±0.39 (15,627)1.78±0.42 (12,378)1.61±0.43 (28,005)
Serum LDL-cholesterol (mmol/l)3.19±0.81 (14,997)3.18±0.79 (11,836)3.18±0.80 (26,833)
Fasting plasma glucose (mmol/l)5.82±1.27 (15,685)5.39±0.93 (12,395)5.63±1.15 (28,080)
Blood hemoglobin A1c (%)5.78±0.74 (10,849)5.64±0.54 (10,169)5.71±0.66 (21,018)
Blood urea nitrogen (mmol/l)5.61±2.86 (8,889)5.07±2.28 (8,162)5.36±2.61 (17,051)
Serum creatinine (μmol/l)88.3±116.2 (14,545)63.1±82.5 (11,225)77.3±103.6 (25,770)
eGFR (ml/min/1.73 m−2)77.2±18.0 (14,545)80.3±17.5 (11,225)78.5±17.9 (25,770)
Serum uric acid (μmol/l)372±79 (14,368)273±62 (10,900)329±87 (25,268)
Serum C-reactive protein (μg/l)1573±6428 (5,793)1207±4107 (4,938)1405±5486 (10,731)
White blood cells (103/μl)5.94±1.73 (12,521)5.03±1.45 (9,419)5.55±1.68 (21,940)
Red blood cells (104/μl)461±46 (12,651)415±36 (9,500)441±47 (22,151)
Hemoglobin (g/l)147±13 (12,651)127±13 (9,501)139±16 (22,152)
Hematocrit (%)43.3±3.7 (12,642)37.5±3.4 (9,497)40.8±4.6 (22,139)
Platelets (104/μl)23.1±5.5 (12,473)23.8±6.2 (9,398)23.4±5.8 (21,871)

a Values in parentheses indicate the numbers of measurements taken. Quantitative data are the means ± SD. FEV1%, forced expiratory volume in 1 sec percentage; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate (ml/min/1.73 m−2) = 194 × [age (years)]−0.287 × [serum creatinine (mg/dl)]−1.094 × [0.739 if female].

Table IV

Characteristics of subjects with hypertension and controls: cross-sectional analysis in March 2014.

Table IV

Characteristics of subjects with hypertension and controls: cross-sectional analysis in March 2014.

ParameterSubjects with hypertensionaControlsaP-value
No. of subjects22503777
Age (years)61.1±10.7 (2,250)50.1±12.4 (3,777)<0.0001
Gender (male/female, %)62.6/37.451.5/48.5<0.0001
Height (cm)161.3±9.4 (2,207)163.2±9.0 (3,747)<0.0001
Weight (kg)63.1±12.7 (2,205)59.7±11.6 (3,747)<0.0001
Body mass index (kg/m2)24.1±3.6 (2,205)22.3±3.1 (3,747)<0.0001
Waist circumference (cm)84.0±9.5 (1,986)78.5±8.5 (3,619)<0.0001
Alcohol consumption (%)52.0 (2,250)46.0 (3,777)<0.0001
Current or former smoker (%)47.7 (2,250)44.5 (3,777)0.0147
Systolic blood pressure (mmHg)133±15 (2,200)113±11 (3,745)<0.0001
Diastolic blood pressure (mmHg)83±12 (2,200)70±10 (3,745)<0.0001
Mean blood pressure (mmHg)99±12 (2,200)84±9 (3,745)<0.0001
Ocular tension (right, mmHg)13.9±3.0 (722)13.3±2.9 (1,339)<0.0001
Functional vital capacity (l)3.12±0.80 (768)3.39±0.80 (1,475)<0.0001
FEV1% (%)80.4±6.38 (768)81.7±6.6 (1,475)<0.0001
Serum albumin (g/l)44.5±3.0 (1,715)44.7±2.4 (2,497)0.0302
Serum total cholesterol (mmol/l)5.19±0.90 (2,230)5.23±0.88 (3,720)0.0921
Serum triglyceride (mmol/l)1.43±0.96 (2,215)1.16±0.79 (3,721)<0.0001
Serum HDL-cholesterol (mmol/l)1.59±0.44 (2,213)1.70±0.45 (3,721)<0.0001
Serum LDL-cholesterol (mmol/l)3.15±0.79 (2,212)3.19±0.81 (3,720)0.0632
Fasting plasma glucose (mmol/l)5.90±1.36 (2,238)5.40±0.96 (3,718)<0.0001
Blood hemoglobin A1c (%)5.84±0.78 (1,782)5.59±0.59 (2,681)<0.0001
Blood urea nitrogen (mmol/l)5.72±2.68 (1,691)4.86±1.23 (2,410)<0.0001
Serum creatinine (μmol/l)88.5±127.4 (2,162)64.8±15.1 (3,414)<0.0001
eGFR (ml/min/1.73 m−2)71.2±18.3 (2,162)80.1±14.7 (3,414)<0.0001
Serum uric acid (μmol/l)349±88 (2,139)312±81 (3,392)<0.0001
Serum C-reactive protein (μg/l)1832±9666 (775)826±3359 (1,338)0.0005
White blood cells (103/μl)5.51±1.74 (1,573)5.31±1.63 (3,034)0.0001
Red blood cells (104/μl)436±48 (1,577)437±43 (3,046)0.1928
Hemoglobin (g/l)139±16 (1,577)137±15 (3,046)0.0017
Hematocrit (%)40.4±4.4 (1,576)40.1±4.2 (3,042)0.0186
Platelets (104/μl)21.8±5.5 (1,557)22.6±5.3 (3,011)<0.0001

a Values in parentheses indicate the numbers of measurements taken. Quantitative data are the means ± SD. eGFR, estimated glomerular filtration rate (ml/min/1.73 m−2) = 194 × [age (years)]−0.287 × [serum creatinine (mg/dl)]−1.094 × [0.739 if female]; HDL, high density lipoprotein; LDL, low density lipoprotein.

The association of the 13 SNPs with the prevalence of hypertension was analyzed with a generalized estimating equation and with adjustment for age, gender, BMI and smoking status (Table V). The rs2116519 (C→T) SNP of the family with sequence similarity 78, member B gene (FAM78B, recessive model), rs6929846 (T→C) of the butyrophilin, subfamily 2, member A1 gene (BTN2A1, dominant model), rs146021107 (G→-) of the pancreatic and duodenal homeobox 1 gene (PDX1, dominant model) and rs1671021 (G→A) of the lethal giant larvae homolog 2 gene (LLGL2, dominant model) were significantly (P<0.05) associated with the prevalence of hypertension.

Table V

Association of polymorphisms with hypertension analyzed for 5-year longitudinal data with a generalized estimating equation.

Table V

Association of polymorphisms with hypertension analyzed for 5-year longitudinal data with a generalized estimating equation.

Gene or locusSNPGenotype HypertensionaControlsaP-value (dominant model)bP-value (recessive model)c
FAM78Brs2116519 (C→T)TT1,888 (32.3)6,649 (30.3)0.30390.0266
TC2,959 (50.7)11,046 (50.3)
CC991 (17.0)4,279 (19.5)
3q28rs9846911 (A→G)AA5,033 (86.2)19,102 (86.9)0.16290.1620
AG759 (13.0)2,756 (12.5)
GG46 (0.8)116 (0.5)
ALPK1rs2074379 (G→A)AA2,707 (46.4)10,004 (45.5)0.73300.2596
AG2,560 (43.9)9,736 (44.3)
GG571 (9.8)2,234 (10.2)
ALPK1rs2074380 (G→A)GG4,905 (84.0)18,656 (84.9)0.11240.1496
GA885 (15.2)3,165 (14.4)
AA48 (0.8)153 (0.7)
ALPK1rs2074381 (A→G)AA4,981 (85.3)18,815 (85.6)0.23900.4732
AG821 (14.1)3,038 (13.8)
GG36 (0.6)121 (0.6)
ALPK1rs2074388 (G→A)AA2,714 (46.5)10,013 (45.6)0.70430.2637
AG2,552 (43.7)9,721 (44.2)
GG572 (9.8)2,240 (10.2)
BTN2A1rs6929846 (T→C)CC4,484 (76.8)17,333 (78.9)0.00130.3602
CT1,275 (21.8)4,365 (19.9)
TT79 (1.4)276 (1.3)
THBS2rs8089 (T→G)TT4,895 (83.8)18,159 (82.6)0.74070.9741
TG902 (15.5)3,615 (16.5)
GG41 (0.7)200 (0.9)
PDX1rs146021107 (G→-)GG1,745 (29.9)5,983 (27.2)0.00310.2885
G/-2,839 (48.6)11,049 (50.3)
-/-1,254 (21.5)4,942 (22.5)
F7rs6046 (G→A)GG5,104 (87.4)19,187 (87.3)0.14780.8979
GA715 (12.2)2,693 (12.3)
AA19 (0.3)94 (0.4)
LLGL2rs1671021 (G→A)AA4,187 (71.7)16,353 (74.4)0.03720.3881
AG1,521 (26.1)5,223 (23.8)
GG130 (2.2)398 (1.8)
ILF3rs2569512 (G→A)GG2,563 (43.9)9,525 (43.3)0.37650.2560
GA2,605 (44.6)10,180 (46.3)
AA670 (11.5)2,269 (10.3)
CELSR1rs6007897 (C→T)TT5,671 (97.1)21,303 (96.9)0.6353not determined
TC167 (2.9)671 (3.1)
CC0 (0)0 (0)

{ label (or @symbol) needed for fn[@id='tfn5-ijmm-35-05-1189'] } The prevalence of hypertension was compared between 2 groups (the dominant or recessive model) for each polymorphism with adjustment for age, gender, body mass index and smoking status.

a Values indicate the numbers of measurements taken, with the percentages in parentheses;

b dominant model: AA vs. AB + BB (A, major allele; B, minor allele);

c recessive model (AA + AB vs. BB). P-values of <0.05 are shown in bold. SNPs, single nucleotide polymorphisms.

The association between the prevalence of hypertension and age analyzed longitudinally with a generalized estimating equation according to the SNP genotype is shown in Fig. 1. The prevalence of hypertension was greater in the combined group of subjects with the TT or TC genotypes of rs2116519 of FAM78B than in those with the CC genotype from 40 to 90 years of age (Fig. 1A), in the combined group of subjects with the CT or TT genotypes of rs6929846 of BTN2A1 than in those with the CC genotype (Fig. 1B), in subjects with the GG genotype of rs146021107 of PDX1 than in the combined group of subjects with the G/- or -/- genotypes (Fig. 1C), and in the combined group of subjects with the AG or GG genotypes of rs1671021 of LLGL2 than in those with the AA genotype (Fig. 1D).

Given that 4 SNPs were significantly associated with hypertension, the association of these SNPs with systolic, diastolic, or mean BP in all individuals or individuals not taking any anti-hypertensive medication were analyzed with a generalized linear mixed-effect model, with adjustment for age, gender, BMI and smoking status (Table VI). The rs6929846 polymorphism of BTN2A1 was significantly associated with systolic, diastolic and mean BP in the dominant model among all individuals or individuals not taking any anti-hypertensive medication, with the T allele being associated with an increased BP. The rs146021107 SNP of PDX1 was significantly associated with systolic BP in the dominant model among all individuals or individuals not taking any anti-hypertensive medication, with the G allele being associated with an increased BP. The rs2116519 polymorphism of FAM78B was significantly associated with diastolic BP in the recessive model among individuals not taking any anti-hypertensive medication, with the T allele being associated with a high BP. The rs1671021 SNP of LLGL2 was significantly associated with diastolic and mean BP in the dominant model among individuals not taking any anti-hypertensive medication, with the G allele being associated with a high BP.

Table VI

Association of polymorphisms with systolic, diastolic, or mean BP in all individuals or individuals not taking any anti-hypertensive medication analyzed for 5-year longitudinal data with a generalized linear mixed-effect model.

Table VI

Association of polymorphisms with systolic, diastolic, or mean BP in all individuals or individuals not taking any anti-hypertensive medication analyzed for 5-year longitudinal data with a generalized linear mixed-effect model.

GeneSNPBP (mmHg)Dominant modela
P-valueRecessive modela
P-value
All individuals
FAM78Brs2116519 (C→T)TT (8,537)TC + CC (19,275)TT + TC (2,2542)CC (5,270)
Systolic121.0±16.7120.4±16.10.3818120.7±16.5120.1±15.70.5823
Diastolic74.9±12.574.6±12.10.126074.8±12.474.1±11.80.0823
Mean90.2±13.189.9±12.60.172290.1±12.989.4±12.20.1814
BTN2A1rs6929846 (T→C)CC (21,817)CT + TT (5,995)CC + CT (27,457)TT (355)
Systolic120.4±16.2121.2±16.70.0061120.6±16.3121.4±15.40.1369
Diastolic74.5±12.275.2±12.40.002374.7±12.375.2±11.00.2483
Mean89.8±12.790.5±13.00.001990.0±12.890.6±11.70.1748
PDX1rs146021107 (G→-)GG (7,728)G/- + -/- (20,084)GG + G/- (21,616)-/- (6,196)
Systolic121.1±17.1120.4±16.00.0284120.8±16.4120.0±16.10.3884
Diastolic74.5±12.874.7±12.10.271974.8±12.374.4±12.10.9222
Mean90.1±13.390.0±12.50.102990.1±12.889.6±12.50.6821
LLGL2rs1671021 (G→A)AA (20,540)AG + GG (7,272)AA + AG (27,284)GG (528)
Systolic120.4±16.2121.2±16.60.1943120.6±16.3121.6±16.10.9056
Diastolic74.5±12.275.2±12.40.128074.7±12.375.8±12.70.4665
Mean89.8±12.790.5±12.90.131590.0±12.891.1±12.80.7203
Individuals not taking any anti-hypertensive medication
FAM78Brs2116519 (C→T)TT (8,132)TC + CC (18,370)TT + TC (2,1459)CC (5,043)
Systolic120.5±16.7119.9±16.00.2563120.2±16.4119.7±15.60.5041
Diastolic74.6±12.574.4±12.10.203974.6±12.473.9±11.70.0495
Mean89.9±13.089.6±12.60.194889.8±12.989.1±12.10.1248
BTN2A1rs6929846 (T→C)CC (20,807)CT + TT (5,695)CC + CT (26,163)TT (339)
Systolic120.0±16.1120.7±16.60.0017120.1±16.3120.8±15.30.1734
Diastolic74.3±12.275.0±12.40.000874.4±12.375.0±10.80.2059
Mean89.5±12.790.2±13.00.000589.7±12.790.3±11.50.1678
PDX1rs146021107 (G→-)GG (7,328)G/- + -/- (19,174)GG + G/- (20,580)-/- (5,922)
Systolic120.6±17.1120.0±15.90.0132120.3±16.3119.5±16.00.2565
Diastolic74.2±12.874.5±12.00.396374.5±12.374.2±12.10.8832
Mean89.7±13.389.7±12.50.108189.8±12.889.3±12.50.7018
LLGL2rs1671021 (G→A)AA (19,569)AG + GG (6,933)AA + AG (26,005)GG (497)
Systolic119.9±16.2120.7±16.50.0891120.1±16.3121.4±16.10.6847
Diastolic74.2±12.275.0±12.40.046874.4±12.275.7±12.70.2512
Mean89.5±12.790.2±12.90.047189.6±12.790.9±12.800.3889

{ label (or @symbol) needed for fn[@id='tfn9-ijmm-35-05-1189'] } Systolic, diastolic, or mean BP was compared between 2 groups (the dominant or recessive model) for each polymorphism with adjustment for age, gender, body mass index and smoking status.

a Values in parentheses indicate the numbers of measurements taken. Data for BP are the means ± SD. P-values of <0.05 are shown in bold. BP, blood pressure. SNPs, single nucleotide polymorphisms.

The association between systolic or diastolic BP and age in individuals not taking any anti-hypertensive medication was analyzed longitudinally according to genotype with a generalized linear mixed-effect model (Fig. 2). Systolic (Fig. 2A) and diastolic (Fig. 2B) BP were greater in the combined group of individuals with the CT or TT genotypes of rs6929846 of BTN2A1 than in those with the CC genotype from 40 to 90 years of age. Systolic BP was greater in subjects with the GG genotype of rs146021107 of PDX1 than in the combined group of individuals with the G/- or -/- genotypes (Fig. 2C). Diastolic BP was greater in the combined group of individuals with the AG or GG genotypes of rs1671021 of LLGL2 than in those with the AA genotype (Fig. 2D).

Discussion

Given that genetic factors, as well as interactions between multiple genes and environmental factors are important in the development of hypertension (1), the ability to predict the risk of developing hypertension on the basis of genetic variants would be beneficial for the personalized prevention of this condition. In this study, we demonstrated that rs6929846 (T→C) of BTN2A1 was significantly associated with the prevalence of hypertension and also with systolic, diastolic, and mean BP in community-dwelling Japanese individuals, with the minor T allele representing a risk factor for hypertension.

We have previously reported that rs6929846 of BTN2A1 is significantly associated with hypertension in a cross-sectional study of a different hospital-based population (31). We also observed the association of this polymorphism with hypertension in a previous cross-sectional analysis of the Inabe Health and Longevity Study (26). The results of the present longitudinal population-based study are thus consistent with these previous observations (26,31) and validate the association of rs6929846 of BTN2A1 with hypertension.

BTN2A1 is a cell-surface transmembrane glycoprotein and a member of the butyrophilin superfamily of proteins. Many of these proteins regulate immune function, and polymorphisms within the coding sequences of the corresponding genes have been associated with the predisposition to inflammatory diseases (32). We have previously demonstrated that the T allele of rs6929846 of BTN2A1 is associated with an increased risk of developing myocardial infarction and with an increased transcriptional activity of BTN2A1 (15). The serum concentration of high-sensitivity C-reactive protein was significantly greater in individuals in the combined group of CT or TT genotypes for this SNP than in those with the CC genotype among healthy subjects without neoplastic, infectious, or inflammatory disease (15,33). These observations suggest that the T allele of rs6929846 of BTN2A1 may accelerate inflammatory processes.

Previous studies have suggested that chronic vascular inflammation influences BP and vascular remodeling (3437). Systolic and diastolic BP, as well as pulse pressure were thus found to be positively associated with the plasma concentration of interleukin-6 in healthy men (34). The plasma concentration of high-sensitivity C-reactive protein was also greater in individuals with hypertension than in the controls, and it was shown to be positively associated with systolic BP and pulse pressure (35). In addition, oxidative stress and vascular inflammation have been shown to influence BP, suggesting that chronic inflammation may play a key role in the pathogenesis of hypertension (36,37). In this study, we demonstrated that rs6929846 of BTN2A1 was significantly associated with hypertension, with the minor T allele representing a risk factor for this condition. The enhancement of chronic inflammation by the T allele of rs6929846 may account for its association with hypertension, although the molecular mechanisms underlying the effects of this polymorphism on the development of hypertension remain to be elucidated.

In a previous meta-analysis of cohort studies, a reduction of 10 mmHg in systolic or 5 mmHg in diastolic BP was estimated to result in a 22–25% decrease in the incidence of coronary artery disease and a 36–41% decrease in that of stroke (38). In our longitudinal analysis, systolic, diastolic and mean BP were each increased by 1 mmHg in individuals with the TT genotype of rs6929846 of BTN2A1 compared with those with the CC genotype. Such a difference is small at the individual level and may not have practical clinical implications. However, even small increments in BP have important effects on cardiovascular morbidity and mortality at the population level, given the high incidence of coronary artery disease, stroke and chronic kidney disease. The reduction in the mortality rate estimated for each 2-mmHg decrease in systolic BP is 4% for coronary artery disease and 6% for stroke (39). Small differences in average BP at the population level thus result in significant differences in the population mortality rate (39).

In this study, we observed that the SNPs of PDX1, LLGL2 and FAM78B were also associated with the prevalence of hypertension, as well as with systolic BP among all individuals and individuals not taking any anti-hypertensive medication (PDX1), with diastolic and mean BP among individuals without anti-hypertensive medication (LLGL2), or with diastolic BP among individuals without anti-hypertensive medication (FAM78B). FAM78B is located at 1q24.1, which has previously been suggested to harbor susceptibility loci for hypertension (40) and type 2 diabetes mellitus (41), although the function of the gene remains unclear. PDX1 is a transcriptional activator at several genes, including those for insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 (NCBI Gene). It contributes to the early development of the pancreas and plays an important role in the glucose-dependent regulation of insulin gene expression (42). A rare frameshift variant of PDX1 was previously found to associated with type 2 diabetes mellitus (43). We have previously demonstrated that rs146021107 of PDX1 is significantly associated with myocardial infarction (18,20), although, to the best of our knowledge, the association of PDX1 polymorphisms with hypertension has not yet been reported. LLGL2 plays a role in asymmetric cell division, the establishment of epithelial cell polarity and cell migration (44,45). We have previously demonstrated that rs1671021 of LLGL2 is associated with ischemic stroke (16), although, to the best of our knowledge, variants of LLGL2 have not yet been associated with hypertension.

The present study had certain limitations: i) given that the study subjects comprised only Japanese individuals, further studies are required on other ethnic groups. ii) It is possible that rs6929846 of BTN2A1 is in linkage disequilibrium with other polymorphisms in BTN2A1 or in nearby genes that are actually responsible for the development of hypertension. iii) The functional relevance of rs6929846 of BTN2A1 to the pathogenesis of hypertension remains unclear.

In conclusion, the present results suggest that BTN2A1 is a susceptibility gene for essential hypertension in Japanese individuals. The determination of the genotype for rs6929846 may prove informative for the assessment of the genetic risk for hypertension in such individuals.

Acknowledgments

This study was supported by the CREST, Japan Science and Technology Agency (to Y.Y. and I.T.), and by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 24590746 to Y.Y.).

References

1 

Lifton RP, Gharavi AG and Geller DS: Molecular mechanisms of human hypertension. Cell. 104:545–556. 2001. View Article : Google Scholar : PubMed/NCBI

2 

Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI and de Geus EJ: Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension. 45:80–85. 2005. View Article : Google Scholar

3 

Agarwal A, Williams GH and Fisher ND: Genetics of human hypertension. Trends Endocrinol Metab. 16:127–133. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Kannel WB: Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol. 85:251–255. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, et al: American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors Stroke. 28:1507–1517. 1997. View Article : Google Scholar

6 

Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M and Koyama A: Risk factors for chronic kidney disease in a community-based population: A 10-year follow-up study. Kidney Int. 71:159–166. 2007. View Article : Google Scholar

7 

Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al: CHARGE-HF consortium: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 478:103–109. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Wain LV, Verwoert GC, O’Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M, Rice KM, Henneman P, Smith AV, et al: Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 43:1005–1011. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, et al: Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 41:666–676. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, et al: Genome-wide association study of blood pressure and hypertension. Nat Genet. 41:677–687. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447:661–678. 2007. View Article : Google Scholar : PubMed/NCBI

12 

Adeyemo A, Gerry N, Chen G, Herbert A, Doumatey A, Huang H, Zhou J, Lashley K, Chen Y, Christman M, et al: A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet. 5:e10005642009. View Article : Google Scholar : PubMed/NCBI

13 

Kato N, Miyata T, Tabara Y, Katsuya T, Yanai K, Hanada H, Kamide K, Nakura J, Kohara K, Takeuchi F, et al: High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project. Hum Mol Genet. 17:617–627. 2008. View Article : Google Scholar

14 

Tabara Y, Kohara K, Kita Y, Hirawa N, Katsuya T, Ohkubo T, Hiura Y, Tajima A, Morisaki T, Miyata T, et al: Global Blood Pressure Genetics Consortium: Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: The Japanese Millennium Genome Project. Hypertension. 56:973–980. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Yamada Y, Nishida T, Ichihara S, Sawabe M, Fuku N, Nishigaki Y, Aoyagi Y, Tanaka M, Fujiwara Y, Yoshida H, et al: Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. Atherosclerosis. 215:145–152. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Yamada Y, Fuku N, Tanaka M, Aoyagi Y, Sawabe M, Metoki N, Yoshida H, Satoh K, Kato K, Watanabe S, et al: Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis. 207:144–149. 2009. View Article : Google Scholar : PubMed/NCBI

17 

Yamada Y, Nishida T, Ichihara S, Kato K, Fujimaki T, Oguri M, Horibe H, Yoshida T, Watanabe S, Satoh K, et al: Identification of chromosome 3q28 and ALPK1 as susceptibility loci for chronic kidney disease in Japanese individuals by a genome-wide association study. J Med Genet. 50:410–418. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Yamada Y, Matsuo H, Segawa T, Watanabe S, Kato K, Hibino T, Yokoi K, Ichihara S, Metoki N, Yoshida H, et al: Assessment of genetic risk for myocardial infarction. Thromb Haemost. 96:220–227. 2006.PubMed/NCBI

19 

Fujimaki T, Kato K, Yoshida T, Oguri M, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nishigaki Y, et al: Association of genetic variants with myocardial infarction in Japanese individuals with chronic kidney disease. Thromb Haemost. 101:963–968. 2009.PubMed/NCBI

20 

Oguri M, Kato K, Yokoi K, Itoh T, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, et al: Association of genetic variants with myocardial infarction in Japanese individuals with metabolic syndrome. Atherosclerosis. 206:486–493. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Ueyama C, Horibe H, Fujimaki T, Oguri M, Kato K and Yamada Y: Association of genetic variants of CELSR1 and 3q28 with hypertension in community-dwelling individuals. Biomed Rep. 1:840–844. 2013.

22 

Shimokata S, Oguri M, Fujimaki T, Horibe H, Kato K and Yamada Y: Association between polymorphisms of the α-kinase 1 gene and type 2 diabetes mellitus in community-dwelling individuals. Biomed Rep. 1:940–944. 2013.

23 

Oguri M, Fujimaki T, Horibe H, Kato K, Ichihara S and Yamada Y: Association of a polymorphism of BTN2A1 with chronic kidney disease in community-dwelling individuals. Biomed Rep. 1:868–872. 2013.

24 

Fujimaki T, Horibe H, Oguri M, Kato K and Yamada Y: Association of genetic variants of the α-kinase 1 gene with myocardial infarction in community-dwelling individuals. Biomed Rep. 2:127–131. 2014.PubMed/NCBI

25 

Horibe H, Ueyama C, Fujimaki T, Oguri M, Kato K, Ichihara S and Yamada Y: Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals. Mol Med Rep. 9:808–812. 2014.PubMed/NCBI

26 

Murakata Y, Fujimaki T and Yamada Y: Association of a butyrophilin, subfamily 2, member A1 gene polymorphism with hypertension. Biomed Rep. 2:818–822. 2014.PubMed/NCBI

27 

Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M and Morgenstern BZ: Human blood pressure determination by sphygmomanometry. Circulation. 88:2460–2470. 1993. View Article : Google Scholar : PubMed/NCBI

28 

Itoh Y, Mizuki N, Shimada T, Azuma F, Itakura M, Kashiwase K, Kikkawa E, Kulski JK, Satake M and Inoko H: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics. 57:717–729. 2005. View Article : Google Scholar : PubMed/NCBI

29 

Hanley JA, Negassa A, Edwardes MD and Forrester JE: Statistical analysis of correlated data using generalized estimating equations: An orientation. Am J Epidemiol. 157:364–375. 2003. View Article : Google Scholar : PubMed/NCBI

30 

Dean CB and Nielsen JD: Generalized linear mixed models: A review and some extensions. Lifetime Data Anal. 13:497–512. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Horibe H, Kato K, Oguri M, Yoshida T, Fujimaki T, Kawamiya T, Yokoi K, Watanabe S, Satoh K, Aoyagi Y, et al: Association of a polymorphism of BTN2A1 with hypertension in Japanese individuals. Am J Hypertens. 24:924–929. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Arnett HA, Escobar SS and Viney JL: Regulation of costimulation in the era of butyrophilins. Cytokine. 46:370–375. 2009. View Article : Google Scholar : PubMed/NCBI

33 

Oguri M, Kato K, Yoshida T, Fujimaki T, Horibe H, Yokoi K, Watanabe S, Satoh K, Aoyagi Y, Tanaka M, et al: Association of a genetic variant of BTN2A1 with metabolic syndrome in East Asian populations. J Med Genet. 48:787–792. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Chae CU, Lee RT, Rifai N and Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension. 38:399–403. 2001. View Article : Google Scholar : PubMed/NCBI

35 

Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, Siepi D, Bagaglia F and Mannarino E: Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J Hypertens. 21:1841–1846. 2003. View Article : Google Scholar : PubMed/NCBI

36 

Savoia C and Schiffrin EL: Inflammation in hypertension. Curr Opin Nephrol Hypertens. 15:152–158. 2006.PubMed/NCBI

37 

Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I and Stefanadis C: Essential hypertension: Is there a role for inflammatory mechanisms? Cardiol Rev. 17:216–221. 2009. View Article : Google Scholar : PubMed/NCBI

38 

Law MR, Morris JK and Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 338:b16652009. View Article : Google Scholar : PubMed/NCBI

39 

Stamler J, Rose G, Stamler R, Elliott P, Dyer A and Marmot M: INTERSALT study findings. Public health and medical care implications. Hypertension. 14:570–577. 1989. View Article : Google Scholar : PubMed/NCBI

40 

Ehret GB, O’Connor AA, Weder A, Cooper RS and Chakravarti A: Follow-up of a major linkage peak on chromosome 1 reveals suggestive QTLs associated with essential hypertension: GenNet study. Eur J Hum Genet. 17:1650–1657. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Shriner D, Adeyemo A and Rotimi CN: Joint ancestry and association testing in admixed individuals. PLoS Comput Biol. 7:e10023252011. View Article : Google Scholar

42 

Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL and Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 15:106–110. 1997. View Article : Google Scholar : PubMed/NCBI

43 

Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H, Grarup N, Sigurdsson A, Helgadottir HT, Johannsdottir H, Magnusson OT, Gudjonsson SA, et al: Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet. 46:294–298. 2014. View Article : Google Scholar : PubMed/NCBI

44 

Müsch A, Cohen D, Yeaman C, Nelson WJ, Rodriguez-Boulan E and Brennwald PJ: Mammalian homolog of Drosophila tumor suppressor lethal (2) giant larvae interacts with basolateral exocytic machinery in Madin-Darby canine kidney cells. Mol Biol Cell. 13:158–168. 2002. View Article : Google Scholar : PubMed/NCBI

45 

Yasumi M, Sakisaka T, Hoshino T, Kimura T, Sakamoto Y, Yamanaka T, Ohno S and Takai Y: Direct binding of Lgl2 to LGN during mitosis and its requirement for normal cell division. J Biol Chem. 280:6761–6765. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May-2015
Volume 35 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yamada Y, Matsui K, Takeuchi I, Oguri M and Fujimaki T: Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study. Int J Mol Med 35: 1189-1198, 2015
APA
Yamada, Y., Matsui, K., Takeuchi, I., Oguri, M., & Fujimaki, T. (2015). Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study. International Journal of Molecular Medicine, 35, 1189-1198. https://doi.org/10.3892/ijmm.2015.2151
MLA
Yamada, Y., Matsui, K., Takeuchi, I., Oguri, M., Fujimaki, T."Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study". International Journal of Molecular Medicine 35.5 (2015): 1189-1198.
Chicago
Yamada, Y., Matsui, K., Takeuchi, I., Oguri, M., Fujimaki, T."Association of genetic variants with hypertension in a longitudinal population-based genetic epidemiological study". International Journal of Molecular Medicine 35, no. 5 (2015): 1189-1198. https://doi.org/10.3892/ijmm.2015.2151